PDS Biotechnology (NASDAQ:PDSB) Shares Down 5.8% – What’s Next?

PDS Biotechnology Co. (NASDAQ:PDSB) was down 5.8% during mid-day trading on Friday . The company traded as low as $1.42 and last traded at $1.46. Approximately 261,041 shares traded hands during trading, an increase of 18% from the average daily volume of 221,346 shares. The stock had previously closed at $1.55.

Analyst Ratings Changes

PDSB has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $21.00 target price on shares of PDS Biotechnology in a report on Wednesday, December 18th. StockNews.com lowered shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, November 9th. Finally, B. Riley reduced their target price on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, November 25th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, PDS Biotechnology currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

PDS Biotechnology Trading Down 5.8 %

The business has a fifty day moving average price of $1.72 and a 200-day moving average price of $2.65. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. The company has a market cap of $54.62 million, a P/E ratio of -1.26 and a beta of 1.88.

Institutional Investors Weigh In On PDS Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of PDSB. Raymond James Financial Inc. acquired a new position in shares of PDS Biotechnology during the 4th quarter worth $26,000. Vontobel Holding Ltd. raised its stake in PDS Biotechnology by 233.3% during the third quarter. Vontobel Holding Ltd. now owns 40,000 shares of the company’s stock worth $153,000 after acquiring an additional 28,000 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of PDS Biotechnology by 9.8% in the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock worth $1,586,000 after acquiring an additional 37,142 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in shares of PDS Biotechnology in the 2nd quarter valued at approximately $120,000. Finally, XTX Topco Ltd grew its holdings in shares of PDS Biotechnology by 241.8% during the 3rd quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock valued at $257,000 after purchasing an additional 47,528 shares during the last quarter. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.